SciELO - Scientific Electronic Library Online

 
vol.31 número7Terapia génica en el cáncer de próstata: ¿Es posible una vacuna?Tratamiento de la disfunción del suelo pélvico índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Actas Urológicas Españolas

versión impresa ISSN 0210-4806

Resumen

RODRIGUEZ GARCIA, N. et al. Natural history of metastasic prostate cancer treated with androgen deprivation therapy and secondary hormonal therapy efficiency. Actas Urol Esp [online]. 2007, vol.31, n.7, pp.714-718. ISSN 0210-4806.

Objective: to analyze metastatic prostate cancer progression in patients treated with hormonal blockade as well as second line hormonal treatments outcomes. Patients and Methods: 199 metastatic patients were selected from a 455 hormonal treated patients pool. Time to biochemical progression was studied with Kaplan Meier analysis and patients were stratified according to pathological differentiation. Second line treatment lasting and efficacy were also assessed. Results: 74 patients out of 192 metastatic patients (56.1%) progressed in terms of PSA. Median time to biochemical progression was 1.7 years (1.2-2.3, CI 95%). We did not find stadistical differences on pathological differentiation (p=0.238). Second line treatment’s efficacy, applied to 41 patients was 34.1%, without any stadistical differences among these treatments. Response treatment median time was 6.8 months without stadistical differences among different treatments (p=0.220). Conclusions: hormonal blockade efficacy in metastatic prostate cancer has a limited value in time in our experience. One third of these patients have a limited response to a second line treatment although this response is even shorter in duration.

Palabras clave : Prostate cancer; Hormonal treatment.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons